文献速递妇科

G-M6——一种齐墩果烷三萜类化合物——作为PARP1抑制与抗癌活性的新型骨架

G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
PubMed 文献 · Gynecol Oncol · 2025-11-12

本研究报道人参皂苷代谢物G-M6为新型PARP1抑制剂,酶学实验IC50为12.38 nM,与奥拉帕利(IC50=15.92 nM,p>0.05)效价相当;在BRCA1缺陷UWB1.289卵巢癌细胞中合成致死选择性指数为4.70,奥拉帕利为2.88;口服80 mg/kg在小鼠移植瘤模型抑瘤率达87.20%,奥拉帕利为86.53%。

要点

  • G-M6酶学抑制PARP1的IC50为12.38 nM,与奥拉帕利(15.92 nM)效价相当(p>0.05)。
  • G-M6在BRCA1缺陷UWB1.289卵巢癌细胞中合成致死选择性指数为4.70,奥拉帕利为2.88。
  • 口服G-M6 80 mg/kg在HR缺陷UWB1.289移植瘤模型抑瘤率为87.20%,奥拉帕利为86.53%。

核心结论

  • G-M6为天然产物来源代谢物,被鉴定为PARP1抑制剂,酶学效价与已批准药物奥拉帕利相当。
  • 该化合物对HR缺陷癌细胞表现出合成致死作用,并在体内减少肿瘤生长。
  • 结合其独特的天然产物来源化学骨架,G-M6是值得进一步临床前研究的先导化合物。

研究设计与样本

  • 研究为G-M6的发现与表征研究,采用酶学实验、五激酶选择性筛选、细胞实验及小鼠移植瘤模型。
  • 体外使用BRCA1缺陷UWB1.289卵巢癌细胞及HR proficient细胞,体内使用UWB1.289肿瘤小鼠移植瘤模型和SW620模型。

主要发现

  • G-M6酶学抑制PARP1的IC50为12.38 nM,奥拉帕利IC50为15.92 nM,两者效价统计学相当(p>0.05)。
  • G-M6对五种激酶的筛选确认其对PARP1相对于这些特定脱靶具有选择性。
  • G-M6在BRCA1缺陷UWB1.289卵巢癌细胞中合成致死选择性指数为4.70,奥拉帕利为2.88。
  • G-M6有效使HR proficient细胞对奥沙利铂和紫杉醇敏感。
  • 口服G-M6 80 mg/kg在HR缺陷UWB1.289小鼠移植瘤模型抑瘤率为87.20%,奥拉帕利为86.53%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The inhibition of Poly (ADP-ribose) polymerase 1 (PARP1) is a clinically validated strategy for treating cancers with homologous recombination (HR) deficiencies. Herein, we report the discovery and characterization of G-M6, a ginsenoside metabolite, as a novel PARP1 inhibitor. METHODS AND RESULTS: G-M6 potently inhibited PARP1 in enzymatic assays with an IC50 of 12.38 nM, demonstrating a potency statistically comparable to the clinical inhibitor Olaparib (IC50 = 15.92 nM, p > 0.05). A screening assay against a panel of five kinases confirmed its selectivity for PARP1 over these specific off-targets. G-M6 induced a superior synthetic lethal effect in BRCA1-deficient UWB1.289 ovarian cancer cells (selectivity index = 4.70) compared to 2.88 for Olaparib. G-M6 also effectively sensitized HR-proficient cells to oxaliplatin and paclitaxel. In vivo, oral administration of G-M6 (80 mg/kg) produced robust tumor growth inhibition (TGI = 87.20 %) in a mouse xenograft model bearing HR-deficient UWB1.289 tumors, outperforming Olaparib (TGI = 86.53 %). This antitumor activity was specific, as no significant activity was observed in the HR-proficient SW620 model. CONCLUSION: G-M6, a natural product-derived metabolite, was identified as a PARP1 inhibitor with enzymatic potency comparable to the approved drug Olaparib. The compound demonstrated synthetic lethality against HR-deficient cancer cells and reduced tumor growth in vivo. These findings, combined with its distinct natural product-derived chemical scaffold, highlight G-M6 as a promising lead compound for further preclinical investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ding M, Li X, Wang H, et al. G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity. Gynecol Oncol. 2025. PMID: 41232210. doi:10.1016/j.ygyno.2025.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。